ArticleBMC pharmacology & toxicology2025
Methimazole-induced reproductive endocrine system disruption and hepatotoxicity: insights from a Trichogaster trichopterus animal model.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative evaluation of tamoxifen and red clover extract on reproductive and hepatic function in female Trichogaster trichopterus: a translational endocrine toxicology study.Journal of molecular histology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethimazole is commonly prescribed for managing hyperthyroidism, although concerns regarding its reproductive and hepatic adverse effects persist. This study aimed to evaluate the dose-dependent effects of methimazole on reproductive endocrine system function and hepatic integrity using an animal model.
methodsAdult female three-spot gourami (Trichogaster trichopterus) were administered intramuscular injections of methimazole at doses of 0.025, 0.05, and 0.1 mg/kg body weight every other day for 20 days. Gonadosomatic Index (GSI), Hepatosomatic Index (HSI), sex steroid hormones (17β-estradiol, testosterone, 17-hydroxyprogesterone), liver enzymes (GOT, GPT), and histological alterations in ovarian and hepatic histology were assessed.
resultsMethimazole significantly reduced GSI in a dose-dependent manner, with the lowest value (3.33%, P < 0.05) observed at the highest dose. Although HSI increased slightly, differences among groups were not significant. Dose-dependent declines were observed in sex steroid hormones, with the most pronounced reduction at 0.1 mg/kg (P < 0.05), indicating significant disruption in steroidogenesis and ovarian function. Liver enzymes activity GOT and GPT were significantly elevated at doses of 0.05 and 0.1 mg/kg (P < 0.05), reflecting hepatic stress and potential hepatotoxicity. Histological analyses demonstrated significant disruption in ovarian follicle maturation, with oocytes arrested at early growth stages at higher methimazole doses. Furthermore, structural liver damage including hepatocyte hypertrophy, inflammation, and necrosis was observed at the highest methimazole dose.
conclusionMethimazole induces notable reproductive and hepatic disturbances, highlighting the importance of monitoring endocrine and hepatic parameters during clinical methimazole therapy, especially in reproductive-age populations. These findings underscore the potential risks associated with methimazole treatment and suggest careful clinical monitoring to mitigate possible reproductive and hepatic adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.